Foetal SSRI exposure linked to increased risk of child’s depression
Children who had been exposed to SSRIs during foetal development were more likely to have depression than those who had not, study finds.
Experiments in rodents suggest that exposure to selective serotonin reuptake inhibitors (SSRIs) during foetal development increases the risk of depression later in life. However, no studies in humans have followed up SSRI-exposed children beyond the age of six years.
Researchers studied data from Finland comparing 15,729 children who had been exposed to SSRIs with 9,651 children whose mothers had a psychiatric disorder but did not take SSRIs during pregnancy.
They found that, up to the age of 14.9 years, the incidence of depression among children in the first group was 8.2% compared with 1.9% in the second group, equating to a 78% increase in the risk of depression.
Reporting in JAACAP (2016;55:359-366), the researchers say that further research is urgently needed to confirm the findings, which they caution must be weighed against the risks of untreated maternal depression.
Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2016.20201103
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now